We have completely sequenced the introns of the human Ltype pyruvate kinase (PK) gene using the published cDNA sequence. Subsequently, DNA from 12 unrelated PK deficiency (PKD) patients of Central European origin was investigated for mutations in this gene by solid-phase sequencing. We detected 10 different mutations, 9 of which result in single amino acid alterations, whereas the tenth destroys a splice site. Eight of the 10 mutations have not been described before. We found 7 missense mutations: G" + A (Gly-332 -+ Sed, Glow + T (Ala-336 + Sed, A'08' -+ G (Asn-361 4 Asp), G"" + A (Ala-392 + Thr), G'e3 + A (Arg-498 + His), + A (Arg-510 + Glnl, Clm -+ T (Arg-532 -+ Trp), one in-frame triplet deletion (del) as well as one insertion (ins): del AAG"= (del Lys-354). ins AGC after Clm3 (ins Ser HE MOST COMMON cause for congenital nonsphemytic hemolytic anemia among glycolytlc enzyme defects is a deficiency of the enzyme pyruvate kinase (PK). In humans as in other mammals, four isozymes exist: PK-L and PK-R are expressed in liver and blood cells, respectively, by the use of diffemt pmmoters of the PK-L gene,' whereas PK-MI (muscle and brain) and PK-M, (fetal and most adult tissues) are produced by alternative splicing during transcription of the PK-M gene? Mutations in the PK-L gene have been described to cause PK deficiency (PKD) . Although the deficiency has been known at the protein level since 1961; the PK-L cDNA was cloned and sequenced only in 1988. 4 No more than five mutations have been described in PK deficiency (PKD) patients of Lebanese, Turkish, and Japanese origin within the last 3 Only recently, 12 additional mutations have been published by Baronciani and Beutler"." and 2 by Kanno et al ." Apart Erom one nonsense, two frameshift, and one splice-site mutation, all mutations found so far are single amino acid substitutions. They are scattered throughout the coding sequence. However, a certain prevalence has been observed of the C''51 -+ T mutation in one Lebanese and two Japanese families, and a strong prevalence of the GIsB + A mutation (10 of 26 alleles) in US patients of Caucasian origin.'""
We have previously reported the biochemical characterization of PKD patients from Central E u r~p e . '~, '~ To determine the mutations causing the PKD in these patients we completely sequenced the human PK-L gene introns and designed primers that cover 100% of the coding sequence including the R-specific exon. With this polymerase chain reaction (PCR)/sequencing approach, we analyzed the DNA of twelve unrelated patients suffering from PKD and detected putative disease-causing mutations in 18 of the 24 alleles investigated. For some of the affected families, we developed carrier diagnostics on the basis of PCR amplification combined with restriction enzyme digestion and allelespecific oligonucleotide hybridization (ASO). after Cys-401). and one splice-site mutation at the border of intron A t o exon 3: g/Gm + alG. Although the enzymatic properties are substantially changed in all PK mutations, only two affected amino acid positions are in or close to the active site. Mutations C' = + T, G-+ A, del AAG'060"u and the splice-site mutation g/Gzw -+ a/G have been detected in two different patients each. Mutation G' = -+ A was found in five different alleles. Haplotype analysis with the A/C polymorphism at position 1705 gave evidence for a single origin of this most frequent mutation in PKD as suggested by Baronciani and Beutler (Proc Natl Acad Sci USA 90:4324,19931. Carrier detection and prenatal diagnosis are now feasible for the affected families.
T MATERIALS AND METHODS

Patients
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origin were investigated. For most of the patients, the enzyme deficiency was characterized according to the International Committee for Standardization in Haemat~logy.'~ The most important hematologic and enzyme-kinetic parameters of these patients are listed in Table 1 .
Only patients 5 and 11 were presumed to be heterozygous for the PKD because of their mild disease course and reticulocytosis and only slightly reduced enzyme activity. They were selected mainly for their abnormal enzyme-kinetic behavior (high Km-PEP variants, ie, variants with a high Michaelis constant for phosphoenal pyruvate). No hematologic data were available for patient 12, but he showed similar severe clinical symptoms as did patient 2, who is also homozygous for the same mutation.
For most of the variant enzymes, a reduced intracellular stability, an altered electrophoretic mobility, and an increased sensitivity against proteolytic degradation (trypsination) were observed. In patients l, 3,6, and 9, a low but detectable PK-M activity was measured at up to 10% to 15% of a normal PK-R activity. DNA was isolated from frozen total blood samples according to Kunkel et Determination of intronic sequences. From the published human PK-L cDNA4 and the PK-L-gene promoter sequence," six pairs of oligonucleotide primers were constructed and used in PCRs to amplify kagments containing introns R-J (Fig l) . Their sequences were as fOllOWS: PR: 5"AGC TAA CTT CAG TAA AGT AC-3'; E3*: 5'- 5"CAG CCC AGC TTC TGT CTC-3'; E12*: 5"GCT GGA GAA CGT AGA CTG-3.
Each primer pair contained one biotinylated primer (marked by an asterisk) that was used to produce singlestranded PCR products after conjugation with streptavidin magnetic beads (Dynal Corp, Oslo, Norway) and alkali denaturation for solidphase sequencing. Sequencing reactions were done by the dideoxynucleotide chain termination method using T7 polymerase (Pharmacia, Uppsala, Sweden) or Sequenase (US Biochemical, Cleveland, OH). 
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RESULTS
PK-L gene introns.
The published sequence of the human PK-L-cDNA4 and the R-type-specific exon RI7 was used to design a set of primers for amplification and sequencing of all PK-L-gene introns. At present, only the sequence of the rat PK-L gene is available.'.'' The human PK-L-gene introns do not differ markedly in length from the rat PK-L gene introns. The overall size of the human gene is about 8,600 bp (Fig 1) compared with the rat gene that comprises 8,360 bp.I7 The sequence of the complete gene will be published elsewhere." From the intronic sequences, primers were chosen to amplify and completely sequence all 12 exons of the patients (Fig l ) . P K gene mutations. The results of the mutation analysis by PCR-sequencing of the DNA of 12 unrelated PKD patients are summarized in Table l . Ten different putative disease-causing mutations were detected on a total of 18 chromosomes. For 6 chromosomes, no mutation could be detected. Of the IO mutations found, 9 were single amino acid changes (7 substitutions, 1 del and 1 ins). Eight of these mutations have not been described before. We also detected the mutation Arg-5 IO + Gln previously reported by Baronciani and Beutler'o.'' to occur in three patients, two homozygous, and one compound heterozygous. Interestingly, as in their study, this is the most prevalent mutation in our population. All these mutations are on the same C haplotype when analyzed for the A/C polymorphism at position 1705, suggesting a common origin of this mutation. The other yetknown mutation is the Arg-498 -+ His substitution, also described by Baronciani and Beutler in a US Caucasian patient." A mutation not detected before in PKD is the splice-site mutation at the border of intron A to exon 3 (5'-taglGGC-3' into 5'-taa/GGC-3'). The only other splice-site mutation associated with PKD which affected the + l position of intron 7 was shown by Kanno five differences as Baronciani and Beutler" noticed: In more than 50 sequences, we always found A ' x R to be a T, A"" + C, GhY4 + A, and CG'*"'"' to be GC. The + A and the + GC changes have already been corrected by Kanno et a1 in the partial genomic sequence,' suggesting a cloning artefact or sequencing error in the originally published sequence. Whether the differences at nucleotide (nt) positions 388 and 393 represent polymorphic sites between Japanese and European populations or are sequencing errors remains to be determined.
Family studies. For the purpose of family studies and prenatal diagnostics, we applied some standard DNA analysis techniques to selected PKD cases. Allele-specific probes were designed that differed only in the mutated nt G's2y (see Materials and Methods). In a dot-blot assay the probes WT (wild type) and MT (mutant type) hybridized specifically to the normal or mutated allele under stringent hybridization conditions (Fig 2) . As the family analysis shows, homozygotes (patient 2) can easily be differentiated from heterozygotes (father and mother to patient 2) as well as from normal persons.
Where the mutation creates or destroys the recognition site of a restriction enzyme, the PCR amplification can be combined with a restriction enzyme analysis. This is shown in Fig 3. The insertion of an AGC after nt 1203 creates a new Pst I site. In DNA carrying the mutation, a 197-bp Pst I fragment is cut into two new 161-and 36-bp fragments. As Fig 3 shows, patient 1 The PCK amplification of genomic DNA fragments with the aid of oliponuclcotitlc primers flanking the mutated site of interest can nlso be applied t o analyze directly some of the Inut;Itions described i n Table I . The 3-bp tlclction AAG''K'""'' can he tlctcctecl in the kunily of patient 6 by the length difference of an amplifietl Htrelll fragment representing this mutation (Fig 4) .
DISCUSSION
In this report. we present I O mutations in the PK-L gene associated with nonspherocytic hemolytic anemia. X of which have not been tlcscribctl before. All. with the except i o n of one splice-site mutation. cause single amino acid suhstitutions in the R/L-type peptide. One of these changes is an insertion of an otltlitional amino acid. Scr. after Cys-40 I . All other changes concern amino acids highly conserved in PK isoenzymes among vertebrates during evolution.'" This nnd the fact that n l l suhstituted amino acids differ markedly in their physicochcnlicol properties from original residues substantiates the assumption that they a l l represent disease-producing Inutntions. Moreover. none of the mutations associated with PKD have been detected in 18 control per-111 6 of I7 patients, we did n o t find 21 mutation in the second nllele. In 4 o f them. bec:we of the co~~rse of the disease and the low-enzyme activity (see Table I ). ;I c o~n - pound heterozygous defect is very probable (patients 7, 8, 9, and 10). Patients 5 and 11, with enzyme activities of about 80% and 50% of normal, are most likely heterozygous. They were included for their abnormal enzyme kinetics (high Km PEP variants), but do not show any serious clinical abnormalities. We sequenced both DNA strands from each exon; however, we cannot completely exclude that we missed the second mutation for technical reasons. But it seems to us more likely that these alleles have mutations in regulative noncoding regions of the gene. If these four patients possess mutations in regulatory regions of the PK gene, their defects must be clarified by analyzing expression at the RNA and/ or protein level. In all cases analyzed, the hematologic and biochemical phenotype matched the putative PKD genotype.
In Fig 5, we summarize our and all previously published data on mutations in the PK-L gene. A wide distribution over the whole coding sequence is apparent, but there is a tendency for mutations to accumulate mainly in exons 5, 8, 9, and 11. Although in nearly all cases the enzyme-kinetic properties of the mutated enzymes were substantially changed (Vmax, Km PEP, activation by F6P, and inhibition by adenosine triphosphate, but never the adenosine diphosphate dependence), only a few amino acids in or close to the active site, according to Muirhead et are affected (Leu-I55 + Pro, Arg-163 -+ Lys, Ala-336 + Ser and possibly the insertion of Ser after Cys-401). The substitution of Ala-336 in the active site by a Ser (patient 5) does not change the stability of the enzyme, but alters the substrate binding affinity of phosphoenolpyruvate considerably ( Table 1) . It is noticeable that seven of twenty-one amino acid substitutions involve arginines, indicating that salt bridges play an important role in the integrity of the PK structure. The correspondence of the high prevalence of the kg-510 + Gln mutation in our population (5 of 24 alleles) with the high frequency of the same mutation in the population investigated by Baronciani and Beutler (10 of 26 alleles) supports the idea of a common single origin of this mutation. The three patients carrying the mutation are of German and English origin, whereas all Czech or Slovak patients analyzed so far do not bear it. A further argument for the single-origin hypothesis is the finding that all these mutations are on the same C haplotype when analyzed for the N C polymorphism at position 1705.
A type of mutation only detected once before in PKD is a splice-site mutation." In contrast to the mutation of the + l position of intron 7, which Kanno et a1 described, the DNA of our two patients is mutated at position -1 in intron 3 (patients 4 and 8, Table 1 ). Currently, we do not have data on the functional consequence of this mutation, such as cDNA sequences of the affected patients. But as an analysis of published splice-site sequences shows, this intron 3' terminal guanosine is absolutely invariant. With no exception in all introns of about 1,550 splice junctions, this position has always been found to be a g: ' so that we can assume that this mutation results in a splicing variant. How it influences expression remains to be determined.
The application of intronic oligonucleotide primers with the powerful PCWgenomic sequencing methodology allows a reliable molecular analysis of putative PKDs. AS0 hybridization and PCR-amplification/restriction enzyme analysis are more convenient alternatives, especially for the tracing of a known defect in family studies and prenatal diagnosis, as we show with three selected PKD families.
In summary, with the description of 10 putative diseasecausing mutations in the PK-L gene, the overall number of published mutations is now 27. This relatively high number allows the conclusion that various point mutations leading to amino acid substitutions are the most common cause of PKD. This situation is very similar to that found in glucose-6-phosphate dehydrogenase or triosephosphate isomerase defi~iencies.~~," Nevertheless, there is one mutation that accounts for more than a quarter of all cases, the substitution of Arg-510 by Gln.
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